Hunter David J, Hellio Le Graverand-Gastineau Marie-Pierre
Division of Research, New England Baptist Hospital, 125 Parker Hill Avenue, Boston, MA 02120, USA.
Med Clin North Am. 2009 Jan;93(1):223-34, xiii. doi: 10.1016/j.mcna.2008.07.011.
This review describes the potential of disease-modifying osteoarthritis drugs (DMOADs), distinguishing between preventing, retarding, stopping, and reversing disease and what might be clinically meaningful. The authors also describe whether there is any evidence to suggest that one can modify disease, and whether the current tissue that is predominantly focused on, namely, cartilage, is an appropriate target. The methodologic approaches and other obstacles to demonstrating efficacy of these agents in clinical trials are considered. This discussion is a narrative review in a field that is rapidly evolving. It is hoped the reader appreciates the complexity of the field and the likely road ahead to DMOAD development.
本综述描述了改善病情的骨关节炎药物（DMOADs）的潜力，区分了预防、延缓、阻止和逆转疾病以及哪些可能具有临床意义。作者还描述了是否有证据表明可以改变疾病，以及当前主要关注的组织即软骨是否是一个合适的靶点。文中考虑了在临床试验中证明这些药物疗效的方法学途径和其他障碍。本讨论是对一个快速发展领域的叙述性综述。希望读者认识到该领域的复杂性以及DMOADs开发可能的前进道路。
